Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced today the first preclinical data of its lead solid‑tumor candidate ATNM‑400 in non‑small cell lung cancer (NSCLC). Presented at the AACR‑NCI‑EORTC International Conference on Molecular Targets and Cancer Therapeutics, the data demonstrate 3‑5× greater tumor‑growth inhibition compared with frontline osimertinib, second‑line Dato‑DXd, and third‑line amivantamab, underscoring ATNM‑400’s potency as an alpha‑emitter‑armed antibody radioconjugate.
The study also revealed a synergistic effect when ATNM‑400 was combined with osimertinib, achieving complete tumor regression in 100 % of tumor‑bearing animals. The synergy is attributed to increased expression of ATNM‑400’s target antigen following EGFR inhibition, highlighting a mechanistic advantage over existing EGFR therapies.
These findings validate ATNM‑400’s multi‑tumor potential and support its development in a large, high‑value NSCLC market. The data represent a significant operational milestone for Actinium, indicating progress toward clinical evaluation and expanding the company’s portfolio beyond prostate cancer.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.